Tyenne Injection, Solution, Concentrate
Product Images NDC 65219-592

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Tyenne (NDC 65219-592). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Tye00 0000 01)

A line graph depicting the percentage of ACR20 responders over time (from week 2 to week 24) for three treatment groups: Placebo + MTX (circle markers), Tocilizumab 8 mg/kg + MTX (triangle markers), and Tocilizumab 4 mg/kg + MTX (square markers). The y-axis shows percentage response with standard error bars, and the x-axis shows visits by week number. Tocilizumab 8 mg/kg + MTX group shows the highest response rates, followed by the 4 mg/kg + MTX, then Placebo + MTX.*

FDA Label Image

Principal Display Panel – 80 mg /4 mL Vial Carton (Tye00 0000 02)

Packaging label for TYENNE Tocilizumab-aazg Injection, 80 mg/4 mL (20 mg/mL) concentrate for intravenous infusion after dilution. The carton contains one single-dose vial with prescribing information and a medication guide. Manufactured by Fresenius Kabi USA LLC, the label includes storage instructions to refrigerate and warnings about seal integrity. Barcode and NDC 65219-590-04 are visible.*

FDA Label Image

Principal Display Panel – 200 mg /10 mL Vial Carton (Tye00 0000 03)

The image shows the packaging label for TYENNE Tocilizumab-aazg Injection, 200 mg/10 mL (20 mg/mL) concentrate for intravenous infusion by Fresenius Kabi USA, LLC. The carton includes one single-dose vial and indicates no preservatives, with storage instructions to refrigerate immediately. The label provides active and inactive ingredient details, usage instructions, and barcode information.*

FDA Label Image

Principal Display Panel – 400 mg /20 mL Vial Carton (Tye00 0000 04)

Packaging label for TYENNE injection, Tocilizumab-aazg, 400 mg/20 mL (20 mg/mL) concentrate for intravenous infusion. The label states it is a sterile solution with no preservative and must be refrigerated immediately. The labeler is Fresenius Kabi USA LLC. The carton contains one single-dose vial with a medication guide and prescribing information. Storage instructions and inactive ingredients are also listed.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.